Martin Johnson
YOU?
Author Swipe
View article: Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer
Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer Open
Population pharmacokinetics (popPK) modeling for osimertinib, a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing m…
View article: Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer
Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer Open
Aims Osimertinib is a third‐generation, irreversible, central nervous system‐active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with efficacy in EGFR‐mutated non‐small cell lung cancer (NSCLC). We assessed the …
View article: In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines Open
Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non‐small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many T…
View article: The potential and pitfalls of artificial intelligence in clinical pharmacology
The potential and pitfalls of artificial intelligence in clinical pharmacology Open
Artificial intelligence (AI) involves using data and algorithms to perform activities normally achieved through human intelligence. AI and its key component machine learning contextualize data and enhance decision making to transform how w…
View article: A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment Open
Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in …
View article: Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis Open
Patients with EGFR T790M-positive NSCLC and radiologically detected LM obtained clinical benefit from osimertinib (80 mg qd).
View article: Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study
Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study Open
Background: Osimertinib, a 3rd-generation EGFR-TKI selective for both sensitising and EGFR T790M resistance mutations, has shown efficacy in pts with CNS metastases; encouraging activity has been reported in pts with LM at 160 mg once dail…
View article: Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer Open
Significant elevation of exposure of gefitinib was observed at the time of ILD occurrence, suggesting reduction of CL/F could be associated with ILD-induced AGP elevation. Increase in exposure of gefitinib is unlikely to be a robust predic…
View article: Asenapine pharmacokinetics and tolerability in a pediatric population
Asenapine pharmacokinetics and tolerability in a pediatric population Open
Asenapine was generally safe and well tolerated in pediatric patients aged 10-17 years. PK and safety data were similar to that observed in the adult population. Intrinsic factors had no significant impact on asenapine exposure, indicating…
View article: CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials Open
NCT01802632; NCT02094261.
View article: Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy
Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy Open
Erratum to: Pharm Res
DOI 10.1007/s11095-015-1846-4
There occurred two errors in the above manuscript (Pharm Res. 2015 Dec 30 [Epub ahead of print]). The correct information is as follows:
The differential equations in Appendi…
View article: Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy
Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy Open
The rat hybrid PBPKPD model structure, integrated with in vitro information and human pharmacokinetic and physiological information, constitutes a scientific basis to predict the time course of D2RO in man.